Acadia Pharmaceuticals (NASDAQ:ACAD) Reports NUPLZID® Net Sales Of $120.6 Million In Q3 2020

Acadia Pharmaceuticals (NASDAQ:ACAD) has announced its Q3 2020 financial results in which net sales were up 27% YoY to $120.6 million.

Pimavanserin sales drove Acadia’s robust Q3 performance

Steve Davis, the company’s CEO, said that in Q3 the Acadia drove strong performance with the continued growth of new prescribers of NUPLAZID® for Parkinson’s diseases psychosis. The treatment is on track for supplemental NDA for dementia-related psychosis treatment, and a PDIFA data has been set for April 3, 2021. Davis said that the company continues to advance its late-stage programs and also investing in new opportunities. The company highlighted this recently through the acquisition of CerSci Therapeutics, which helped it in expanding its clinical pipeline with a novel first-in-class, non-opioid, chronic and acute pain program.

The company presented clinical analyses on pimavanserin studies at the 13th Clinical Trials on Alzheimer’s disease (CTAD) meeting. The presentations were titled, “Impact of Pimavanserin on Congentive Measures in Patients with Neurodegenetative Disease: Results from 4 Placebo-Controlled Clinical Studies” and “Impact of Pimavanserin Treatment on Motor Function in Patients with Neurodegentative Disease: Results from 3 Clinical Studies.” In October, the company presented a poster titled “Healthcare resource Utilization and Associated Costs for dementia Patients with Psychosis: A Medicare Database Study.”

Acadia enters partnership with The Lewy Body Dementia Association

Recently the company announced the signing of a collaboration with The Lewy Body Dementia Association (LBDA) on releasing of disease education adaptation of Robin’s Wish© documentary. The film titled “SPARK – Robion Williams and his Battle with Lewy Body Dementia©” will be available to universities and academic research institutions as part of education programming.

During the quarter, the company also made some leadership changes with the appointment of Dr Gudarz Davar as the Executive VP and Research & Development Head. Davar will be reporting to Acadia president Serge Stankovic. Acadia also appointed Elizabeth Garofalo to the Board of Directors.

In Q3 the company reported pimavanserin net sales of $120.6 million compared to $94.6 million in Q3 2019 and 320.7 million in the first nine months of 2020.